EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Physical frailty deteriorates after a 5‐day dexamethasone course in children with acute lymphoblastic leukemia, results of a national prospective study

Emma J Verwaaijen iD, Annelienke M van Hulst, Annelies Hartman, Rob Pieters, Marta Fiocco, Saskia M F Pluijm, Raphaële R L van Litsenburg, Martha A Grootenhuis, Erica L T van den Akker, Marry M van den Heuvel-Eibrink

Cancer Medicine · 2023

DOI: 10.1002/cam4.6779 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Emma J Verwaaijen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. Hauptthemen laut MEDLINE: Frailty, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Sarcopenia. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Stichting de Wonderlijke Reis, Stichting Kinderen Kankervrij.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dexamethasone is important in the treatment for pediatric acute lymphoblastic leukemia (ALL) but induces muscle atrophy with negative consequences for muscle mass, muscle strength, and functional abilities. The aim of this study was to establish the effect of a dexamethasone course on sarcopenia and physical frailty in children with ALL, and to explore prognostic factors.

Methods

Patients with ALL aged 3–18 years were included during maintenance therapy. Patients had a sarcopenia/frailty assessment on the first day of (T1) and on the day after (T2) a 5‐day dexamethasone course. Sarcopenia was defined as low muscle strength in combination with low muscle mass. Prefrailty and frailty were defined as having two or ≥three of the following components, respectively: low muscle mass, low muscle strength, fatigue, slow walking speed, and low physical activity. Chi‐squared and paired t ‐tests were used to assess differences between T1 and T2. Logistic regression models were estimated to explore patient‐ and therapy‐related prognostic factors for frailty on T2.

Results

We included 105 patients, 61% were boys. Median age was 5.3 years (range: 3–18.8). At T1, sarcopenia, prefrailty, and frailty were observed in respectively 2.8%, 23.5%, and 4.2% of patients. At T2, the amount of patients with frailty had increased to 17.7% ( p = 0.002), whereas the number of patients with sarcopenia and prefrailty remained similar. Higher ASMM (odds ratio [OR]: 0.49, 95% CI: 0.28–0.83), stronger handgrip strength (OR: 0.41, 95% CI: 0.22–0.77) and more physical activity minutes per day (OR: 0.98, 95% CI: 0.96–0.99) decreased the risk of frailty at T2. Slower walking performance (OR: 2, 95% CI: 1.2–3.39) increased the risk. Fatigue levels at T1 were not associated with frailty at T2.

Conclusion

Physical frailty increased strikingly after a 5‐days dexamethasone course in children with ALL. Children with poor physical state at start of the dexamethasone course were more likely to be frail after the course.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FrailtyPrecursor Cell Lymphoblastic Leukemia-LymphomaSarcopeniaChildChild, PreschoolFemaleHumansMaleDexamethasoneFatigueGeriatric AssessmentHand StrengthProspective Studies

Stichwörter der Autor:innen

acute lymphoblastic leukemiadexamethasonefrailtymuscle wasting

Substanzen

Dexamethasone

Autor:innen und Institutionen

  • Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Department of Pediatric Physiotherapy, Erasmus Medical Center-Sophia Children's Hospital, Rotterdam, The Netherlands.
  • Mathematical Institute Leiden University, Leiden, The Netherlands.
  • Department of Biomedical Data Science, Section Medical Statistics, Leiden University Medical Center, Leiden, The Netherlands.
  • Department of Pediatrics, Division Pediatric Endocrinology, Obesity Center CGG, Erasmus Medical Center-Sophia Children's Hospital, Rotterdam, The Netherlands.
  • Division of Child Health, Wilhelmina Children's Hospital, Utrecht, The Netherlands.

ORCID-Profile: Emma J Verwaaijen

Förderung

  • Stichting de Wonderlijke Reis
  • Stichting Kinderen Kankervrij

Zitieren

APA

Verwaaijen, E. J., van Hulst, A. M., Hartman, A., Pieters, R., Fiocco, M., Pluijm, S. M. F., van Litsenburg, R. R. L., Grootenhuis, M. A., van den Akker, E. L. T., & van den Heuvel-Eibrink, M. M. (2023). Physical frailty deteriorates after a 5‐day dexamethasone course in children with acute lymphoblastic leukemia, results of a national prospective study. Cancer Medicine. https://doi.org/10.1002/cam4.6779

Vancouver

Verwaaijen EJ, van Hulst AM, Hartman A, Pieters R, Fiocco M, Pluijm SMF, et al. Physical frailty deteriorates after a 5‐day dexamethasone course in children with acute lymphoblastic leukemia, results of a national prospective study. Cancer Medicine. 2023. doi:10.1002/cam4.6779

BibTeX
@article{Verwaaijen2023,
  author = {Verwaaijen, Emma J and van Hulst, Annelienke M and Hartman, Annelies and Pieters, Rob and Fiocco, Marta and Pluijm, Saskia M F and van Litsenburg, Raphaële R L and Grootenhuis, Martha A and van den Akker, Erica L T and van den Heuvel-Eibrink, Marry M},
  title = {Physical frailty deteriorates after a 5‐day dexamethasone course in children with acute lymphoblastic leukemia, results of a national prospective study},
  journal = {Cancer Medicine},
  year = {2023},
  doi = {10.1002/cam4.6779}
}
Kostenlos starten →